Liver-targeting gene therapy lowers mice whole-body SMA symptoms
Gene therapy that selectively delivers the SMN1 gene to the liver reduced alterations related to spinal muscular atrophy (SMA) in a mouse model, restoring muscle size and correcting pancreatic issues. Mice that received liver-specific SMN1 also lived longer, performed better on motor tasks, and had fewer liver problems than untreated…